Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MyomoMYO +0.70%48 Debt-to-Equity is 3.45 as of Jun. 2026, which is 4829% above its 10-year median of 0.07. GuruFocus rates MYO with a GF Score™ of 48/100 and a GF Value™ of $3.15 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 703 Medical Devices & Instruments companies, Myomo ranks worse than 96.3% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Myomo's Debt-to-Equity or its related term are showing as below:
MYO'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.31 Med: 0.07 Max: 3.45
Current: 3.45
During the past 10 years, the highest Debt-to-Equity Ratio of Myomo was 3.45. The lowest was -0.31. And the median was 0.07.
MYO's Debt-to-Equity is ranked worse than 96.3% of 703
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs MYO: 3.45
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Myomo Debt-to-Equity Related Terms
Myomo Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Myomo's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Myomo's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Myomo Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Myomo's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Myomo's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myomo (MYO) has a Debt-to-Equity of 3.45 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Myomo and its competitors. This is 4829% above median its historical median of 0.07. According to the industry distribution chart, Myomo ranks #677 out of 703 companies in the Medical Devices & Instruments industry, placing it in the top 96.3%.
Is Myomo's Debt-to-Equity too high?
Myomo's current Debt-to-Equity of 3.45 is 4829% above median its 10-year median of 0.07. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Myomo's value of 3.45 is 1400% above this industry median. Based on the distribution chart, Myomo ranks #677 out of 703 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Myomo has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Myomo's Debt-to-Equity compare to QTI and NSYS?
According to the Medical Devices & Instruments industry distribution chart, Myomo ranks #677 out of 703 companies for Debt-to-Equity. This places Myomo in the lower half of its industry. The industry median Debt-to-Equity is 0.23. Myomo's value of 3.45 is 1400% above this benchmark. While the company's 10-year median is 0.07 vs. the industry median of 0.23, Myomo has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Myomo's current Debt-to-Equity of 3.45 is 1400% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Myomo and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Myomo's current Debt-to-Equity is 3.45, which is 4829% above median its own 10-year median of 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Myomo stock overvalued right now?
Based on GuruFocus' analysis, Myomo (MYO) is currently considered Possible Value Trap. The stock's GF Value™ is $3.15, compared to a current price of $1.43 — trading 54.6% below its estimated fair value. The current Debt-to-Equity is 3.45, which is 4829% above median its 10-year median of 0.07 and 1400% above the Medical Devices & Instruments industry median of 0.23. Myomo's overall GF Score™ is 48/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Myomo (MYO), the current Debt-to-Equity is 3.45 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Myomo (MYO) Overvalued in 2026?
Based on GuruFocus' analysis, Myomo stock appears to be undervalued.
The current stock price of $1.43 is trading 54.6% below its estimated GF Value™ of $3.15.
GuruFocus considers Myomo to be Possible Value Trap.
Key valuation signals for MYO:
Debt-to-Equity: 3.45 (4829% above median its 10-year median of 0.07)
GF Value™: $3.15 vs. price of $1.43 (54.6% below fair value)
Industry Position: 1400% above the Medical Devices & Instruments median (#677 of 703)
No single metric tells the full story. See the MYO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA). Geographically, it derives maximum revenue from the United States, followed by Germany, and other international.
48GF Score
Get the complete analysis for MYO
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MYO has been successfully added to your 
